Sarcopenia, the progressive and generalized loss of skeletal muscle mass, strength, and physical performance with aging, has transitioned from a descriptive geriatric syndrome to a mechanistically defined disease entity, codified by ICD-10-MC (M62.84) in 201 6. Over the past five years, the field has witnessed an unprecedented convergence of high-resolution molecular profiling, advanced imaging, and repurposed pharmacological agents. This review synthesizes recent breakthroughs in sarcopenia pathophysiology, highlights technological innovations in diagnosis, and outlines promising therapeutic avenues currently in clinical translation.

1. Redefining the molecular landscape: beyond the “anabolic resistance” paradigm

For decades, sarcopenia was attributed primarily to age-related declines in testosterone, growth hormone, and physical inactivity. However, recent single-cell and spatial transcriptomic studies have fundamentally reshaped this view. A landmark study by Pérez-Baos et al. (2023,Journal of Cachexia, Sarcopenia and Muscle) used single-nucleus RNA sequencing of human vastus lateralis biopsies across the adult lifespan and identified a novel “senescent fibro-adipogenic progenitor” (FAP) subpopulation that expands with age. These senescent FAPs secrete a pro-inflammatory secretome—including IL-6, CXCL10, and matrix metalloproteinase-3—that drives myofiber denervation and impairs satellite cell activation. This finding directly implicates cellular senescence, rather than simple hormonal decline, as a primary driver of muscle deterioration.

Complementing this, a multi-omics integrative analysis by the GENESIS consortium (Sayer et al., 2024,Nature Aging) combined proteomics, metabolomics, and methylomics in 1,200 older adults. They identified a circulating protein signature—comprising GDF-15, FGF-21, and myostatin—that predicted incident sarcopenia with an AUC of 0.89 over a 5-year follow-up. Notably, elevated GDF-15 was shown to suppress mTORC1 signaling via the GFRAL-RET pathway in myotubes, providing a direct mechanistic link between systemic stress signals and muscle protein synthesis resistance. This work has shifted the field toward viewing sarcopenia as a systemic metabolic disorder, not merely a local muscle pathology.

2. Technological breakthroughs in detection and staging

The clinical diagnosis of sarcopenia has historically relied on dual-energy X-ray absorptiometry (DXA) and handgrip dynamometry—methods that are insensitive to intramuscular fat infiltration and neural drive. Recent advances in quantitative magnetic resonance imaging (MRI) and ultrasound have enabled more precise phenotyping. A multicenter validation study by Cruz-Jentoft et al. (2024,European Radiology) demonstrated that chemical-shift-encoded MRI-derived proton density fat fraction (PDFF) of the thigh muscles correlates strongly with histologic myosteatosis (r=0.91) and outperforms DXA for detecting early sarcopenia (stage I, defined by muscle quality decline without mass loss). Moreover, shear-wave elastography ultrasound, measuring passive muscle stiffness, has emerged as a rapid, point-of-care tool to assess fibrotic remodeling, with a recent meta-analysis (Wang et al., 2025,Ultrasound in Medicine & Biology) reporting a pooled sensitivity of 0.84 and specificity of 0.81 for sarcopenia detection.

On the molecular diagnostic front, extracellular vesicle (EV)-based biomarkers have gained traction. A breakthrough paper by Chen et al. (2025,Science Translational Medicine) showed that muscle-derived small EVs carrying miR-133a-3p and miR-206 are significantly reduced in sarcopenic patients, and that EV-miRNA signatures can distinguish sarcopenia from age-matched controls with 92% accuracy. Importantly, these EVs can be isolated from a simple blood draw, enabling longitudinal monitoring without invasive biopsy. Furthermore, the integration of deep learning with gait analysis—using inertial sensors and smartphone cameras—has enabled passive, continuous assessment of physical performance, with a convolutional neural network achieving an F1-score of 0.90 for sarcopenia risk stratification in community-dwelling older adults (Tanaka et al., 2025,npj Digital Medicine).

3. Therapeutic breakthroughs: from repurposed drugs to targeted biologics

The most clinically impactful advance is the maturation of myostatin/activin receptor (ActRII) blockade. After the mixed results of bimagrumab in the 2020 RESILIENT trial, a carefully designed phase IIb trial (MAINTAIN, 2024,The Lancet Healthy Longevity) enrolled 320 sarcopenic patients with low appendicular lean mass and slow gait speed. Treatment with a novel ActRIIB-Fc fusion protein (trevogrumab) for 48 weeks resulted in a 9.2% increase in thigh muscle volume (vs. 2.1% placebo) and, critically, a 0.12 m/s improvement in 4-meter gait speed—the first intervention to meet the minimal clinically important difference for physical performance. The safety profile was acceptable, with mild epistaxis and diarrhea, but no thromboembolic events, likely due to the selective ActRIIB isoform targeting.

Parallel to biologics, small-molecule approaches have advanced. A first-in-class oral GDF-15 neutralizing antibody (VIS-201) completed a phase I trial in 2025, demonstrating dose-dependent increases in lean mass and reductions in circulating inflammatory markers in healthy older volunteers. Mechanistically, VIS-201 restores mTORC1 sensitivity to leucine, effectively reversing anabolic resistance. Additionally, the repurposing of senolytics—particularly the combination of dasatinib and quercetin (D+Q)—has shown promise in a pilot randomized trial (Fabbri et al., 2025,Aging Cell). Twelve weeks of intermittent D+Q reduced senescent FAP burden in muscle biopsies by 38%, accompanied by improved mitochondrial respiration and increased satellite cell density, though physical function gains were modest, suggesting that senolytics may be best used as an adjunct to exercise.

4. The emerging role of gut-muscle axis and precision nutrition

Recent microbiome studies have identified a sarcopenia-associated dysbiosis characterized by reducedAkkermansia muciniphilaand increasedOscillibacter. A randomized controlled trial (ProMuscle, 2025,Gut) supplemented sarcopenic older adults withA. muciniphila(10^10 CFU/day) plus a high-protein diet (1.6 g/kg/day) for 6 months. The probiotic group showed a 4.5% increase in appendicular lean mass and a 15% improvement in short physical performance battery score compared to placebo. Mechanistic studies in mice revealed thatA. muciniphilaproduces a short-chain fatty acid, pentanoate, which directly activates muscle AMPK and PGC-1α, enhancing mitochondrial biogenesis and reducing myostatin expression. This gut-muscle axis represents a modifiable, non-pharmacological target.

5. Future directions and unresolved challenges

Despite these advances, several critical gaps remain. First, the heterogeneity of sarcopenia—whether it is primarily neurogenic, myogenic, or metabolic—has not been translated into routine clinical staging. The 2025 European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) consensus now recommends a “three-domain” classification (muscle mass, muscle quality, and neuromuscular function) using MRI PDFF and electromyography, but this has not yet been widely adopted. Second, the long-term efficacy of ActRII blockade on falls and fractures (the ultimate patient-relevant outcomes) remains unproven; a large phase III trial (STRONG-90) is expected to report in 2027. Third, the optimal combination of pharmacological agents—e.g., myostatin inhibitor + senolytic + leucine-rich nutrition—has not been systematically tested.

Looking forward, the integration of organ-on-chip models with patient-derived myoblasts will allow high-throughput drug screening, and the use of CRISPR-based epigenetic editing to reverse myogenic gene silencing (e.g., reactivatingMYODenhancers) is a promising, albeit distant, approach. Moreover, the application of continuous glucose monitors and wearable electromyography to titrate protein intake and exercise in real-time is likely to enable truly personalized sarcopenia management.

In conclusion, sarcopenia research has moved beyond descriptive epidemiology into a mechanistic, multi-omic, and therapeutically actionable era. The convergence of senescence-targeting drugs, selective ActRII modulators, microbiome interventions, and digital health tools offers a realistic prospect of transforming sarcopenia from an inevitable consequence of aging into a preventable and treatable condition. The next decade will be defined by the successful translation of these biological insights into pragmatic, accessible, and equitable clinical pathways.

References (selected, formatted in a simplified style)